|
1
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
3
|
Behm-Ansmant I, Rehwinkel J and Izaurralde
E: MicroRNAs silence gene expression by repressing protein
expression and/or by promoting mRNA decay. Cold Spring Harb Symp
Quant Biol. 71:523–530. 2006. View Article : Google Scholar
|
|
4
|
Chen Y, Zhang L and Hao Q: Candidate
microRNA biomarkers in human epithelial ovarian cancer: Systematic
review profiling studies and experimental validation. Cancer Cell
Int. 13:862013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang JL, Hu Y, Kong X, Wang ZH, Chen HY,
Xu J and Fang JY: Candidate microRNA biomarkers in human gastric
cancer: A systematic review and validation study. PLoS One.
8:e736832013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gaur A, Jewell DA, Liang Y, Ridzon D,
Moore JH, Chen C, Ambros VR and Israel MA: Characterization of
microRNA expression levels and their biological correlates in human
cancer cell lines. Cancer Res. 67:2456–2468. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reynolds EA and Moller KA: A review and an
update on the screening of epithelial ovarian cancer. Curr Probl
Cancer. 30:203–232. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ozols RF, Bookman MA, Connolly DC, Daly
MB, Godwin AK, Schilder RJ, Xu X and Hamilton TC: Focus on
epithelial ovarian cancer. Cancer Cell. 5:19–24. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shan W and Liu J: Epithelial ovarian
cancer: Focus on genetics and animal models. Cell Cycle. 8:731–735.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Farley J, Ozbun LL and Birrer MJ: Genomic
analysis of epithelial ovarian cancer. Cell Res. 18:538–548. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miyamoto M, Takano M, Goto T, Kato M,
Sasaki N, Tsuda H and Furuya K: Clear cell histology as a poor
prognostic factor for advanced epithelial ovarian cancer: A single
institutional case series through central pathologic review. J
Gynecol Oncol. 24:37–43. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shih IeM and Kurman RJ: Ovarian
tumorigenesis: A proposed model based on morphological and
molecular genetic analysis. Am J Pathol. 164:1511–1518. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Comijn J, Berx G, Vermassen P, Verschueren
K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D and van Roy
F: The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Mol Cell.
7:1267–1278. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vandewalle C, Comijn J, De Craene B,
Vermassen P, Bruyneel E, Andersen H, Tulchinsky E, Van Roy F and
Berx G: SIP1/ZEB2 induces EMT by repressing genes of different
epithelial cell-cell junctions. Nucleic Acids Res. 33:6566–6578.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ansieau S, Bastid J, Doreau A, Morel AP,
Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S,
et al: Induction of EMT by twist proteins as a collateral effect of
tumor-promoting inactivation of premature senescence. Cancer Cell.
14:79–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
You J, Li Y, Fang N, Liu B, Zu L, Chang R,
Li X and Zhou Q: MiR-132 suppresses the migration and invasion of
lung cancer cells via targeting the EMT regulator ZEB2. PLoS One.
9:e918272014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gemmill RM, Roche J, Potiron VA, Nasarre
P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA and
Drabkin HA: ZEB1-responsive genes in non-small cell lung cancer.
Cancer Lett. 300:66–78. 2011. View Article : Google Scholar
|
|
22
|
Bindels S, Mestdagt M, Vandewalle C,
Jacobs N, Volders L, Noël A, van Roy F, Berx G, Foidart JM and
Gilles C: Regulation of vimentin by SIP1 in human epithelial breast
tumor cells. Oncogene. 25:4975–4985. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Deering TG, Ogihara T, Trace AP, Maier B
and Mirmira RG: Methyltransferase Set7/9 maintains transcription
and euchromatin structure at islet-enriched genes. Diabetes.
58:185–193. 2009. View Article : Google Scholar :
|
|
24
|
Schneider R, Bannister AJ, Myers FA,
Thorne AW, Crane-Robinson C and Kouzarides T: Histone h3 lysine 4
methylation patterns in higher eukaryotic genes. Nat Cell Biol.
6:73–77. 2004. View
Article : Google Scholar
|
|
25
|
Pradhan S, Chin HG, Estève PO and Jacobsen
SE: SET7/9 mediated methylation of non-histone proteins in
mammalian cells. Epigenetics. 4:383–387. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tao Y, Neppl RL, Huang ZP, Chen J, Tang
RH, Cao R, Zhang Y, Jin SW and Wang DZ: The histone
methyltransferase Set7/9 promotes myoblast differentiation and
myofibril assembly. J Cell Biol. 194:551–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Keating ST, Ziemann M, Okabe J, Khan AW,
Balcerczyk A and El-Osta A: Deep sequencing reveals novel Set7
networks. Cell Mol Life Sci. 71:4471–4486. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kouzarides T: Chromatin modifications and
their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bracken CP, Li X, Wright JA, Lawrence DM,
Pillman KA, Salmanidis M, Anderson MA, Dredge BK, Gregory PA,
Tsykin A, et al: Genome-wide identification of miR-200 targets
reveals a regulatory network controlling cell invasion. EMBO J.
33:2040–2056. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pecot CV, Rupaimoole R, Yang D, Akbani R,
Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, et al:
Tumour angiogenesis regulation by the miR-200 family. Nat Commun.
4:24272013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheng W, Liu T, Wan X, Gao Y and Wang H:
MicroRNA-199a targets CD44 to suppress the tumorigenicity and
multidrug resistance of ovarian cancer-initiating cells. FEBS J.
279:2047–2059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu S, Huang S, Ding J, Zhao Y, Liang L,
Liu T, Zhan R and He X: Multiple microRNAs modulate p21Cip1/Waf1
expression by directly targeting its 3′ untranslated region.
Oncogene. 29:2302–2308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tili E, Michaille JJ and Croce CM:
MicroRNAs play a central role in molecular dysfunctions linking
inflammation with cancer. Immunol Rev. 253:167–184. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yanokura M, Banno K, Kobayashi Y, Kisu I,
Ueki A, Ono A, Masuda K, Nomura h, Hirasawa A, Susumu N, et al:
MicroRNA and endometrial cancer: Roles of small RNAs in human
tumors and clinical applications (Review). Oncol Lett. 1:935–940.
2010.PubMed/NCBI
|
|
36
|
Zhao S, Deng Y, Liu Y, Chen X, Yang G, Mu
Y, Zhang D, Kang J and Wu Z: MicroRNA-153 is tumor suppressive in
glioblastoma stem cells. Mol Biol Rep. 40:2789–2798. 2013.
View Article : Google Scholar : PubMed/NCBI
|
